Objective: We investigated the relationship between serum levels of endocan and disease activity in patients with Fibromyalgia.
Material method: Forty-five patients who met the 2010 ACR FMS criteria and 28 healthy controls were included in the study. To measure the severity of the disease in patients with fibromyalgia (FMS), the symptom severity scale (SSS), the widespread pain index (WPI), and the Visual Analogue Scale (VAS) were evaluated. Serum endocan, Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and CRP values of the patient and control groups were measured.
Results: Patients with FMS had significantly higher serum endocan levels. Mean serum levels of endocan were 0.99 ± 0.28 ng/mL (range: 0.1-2.2) in patients with FMS and 0.63 ± 0.17) ng/mL (range: 0.4 ± 1.1) in control subjects (p <0.05). ROC analysis results for endocan level in the FMS group [AUC (%95 GA): 0.89 (0.81-0.97), sensitivity: %68.9, specificity: %96]. A significant correlation was found between endocan levels and SSS (r:0.33 p: 0.004).
Conclusion: Our study, in which we detected significantly higher endocan levels in patients with FMS compared to controls, supported the use of endocan as an important potential marker for FMS.
Fibromyalgia Endocan Symptom Severity Scale İnflammation , İnflammation Pain
Fibromyalgia Endocan Symptom Severity Scale İnflammation Pain
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Research Article |
Yazarlar | |
Erken Görünüm Tarihi | 1 Ağustos 2023 |
Yayımlanma Tarihi | 19 Temmuz 2023 |
Gönderilme Tarihi | 17 Aralık 2022 |
Kabul Tarihi | 17 Mart 2023 |
Yayımlandığı Sayı | Yıl 2023 Cilt: 40 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.